PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH PROTECTION UNTIL 2037 CANADIAN PATENT COMPLETES INTELLECTUAL. | June 1, 2023
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS RESUMED ITS REVIEW OF THE NEW DRUG SUBMISSION FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS, FOLLOWING ISSUANCE OF A SCREENING ACCEPTANCE. | May 9, 2023
PRESS RELEASE AB SCIENCE SUMMARIZES THE PRESENTATION ON MASITTINIB IN AMYOTROPHIC LATERAL SCLEROSIS MADE AT THE AMERICAN ACADEMY OF NEUROLOGY 2023 ANNUAL.